Terms: = Germ cell tumor AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Prognosis
10 results:
1. Clinical significance of molecular subgroups of polymorphous low-grade neuroepithelial tumor of the young (PLNTY): A small single institutional case series and integrated analysis.
Vuong HG; Alzayadneh E; Reith TP; Eschbacher KL
Pathol Res Pract; 2023 Dec; 252():154922. PubMed ID: 37984047
[TBL] [Abstract] [Full Text] [Related]
2. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with fgfr3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract] [Full Text] [Related]
3. Oncogenic Fusions in Gliomas: An Institutional Experience.
Polivka J; Svajdler M; Priban V; Mracek J; Kasik P; Martinek P; Ptakova N; Sharif Bagheri M; Shetti D; Pesta M; Potuznik P; Topolcan O
Anticancer Res; 2022 Apr; 42(4):1933-1939. PubMed ID: 35347013
[TBL] [Abstract] [Full Text] [Related]
4. Targeting gene fusions in glioma.
Kim PL
Curr Opin Neurol; 2021 Dec; 34(6):840-847. PubMed ID: 34766555
[TBL] [Abstract] [Full Text] [Related]
5. [Master regulators associated with poor prognosis in glioblastoma multiforme].
Kalya MP; Beisbarth T; Kel A
Biomed Khim; 2021 May; 67(3):201-212. PubMed ID: 34142527
[TBL] [Abstract] [Full Text] [Related]
6. Novel targetable FGFR2 and fgfr3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
[TBL] [Abstract] [Full Text] [Related]
7. Comparative proteogenomic characterization of glioblastoma.
Asif S; Fatima R; Krc R; Bennett J; Raza S
CNS Oncol; 2019 Jun; 8(2):CNS37. PubMed ID: 31290679
[No Abstract] [Full Text] [Related]
8. Diffuse gliomas with fgfr3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract] [Full Text] [Related]
9. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated fgfr3 and FGFR1 expression in aggressive ependymomas.
Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ
BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611
[TBL] [Abstract] [Full Text] [Related]
10. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract] [Full Text] [Related]